Laurus Labs — 360° view

Laurus Labs, a company in the Pharmaceuticals industry, reported revenue of ₹2,206 crore and net profit of ₹436 crore for the September 2026 quarter.

Laurus Labs (NSE: LAURUSLABS) closed at ₹2,294.60 on 20 Nov 2026, up 132.5% over the past year. Its market capitalisation is ₹1,23,980 crore and it trades at 92.5 times earnings.

Share price
₹2,294.60 (20 Nov 2026)
Market cap
₹1,23,980 Cr (20 Nov 2026)
P/E
92.53 (20 Nov 2026)
Revenue
₹2,206 Cr (September 2026 quarter)
Net profit
₹436 Cr (September 2026 quarter)
ROCE
17.8% (FY26)
ROE
18.3% (FY26)
Book value
₹112 (FY26)
Dividend yield
0.10% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,488.00 / ₹917.95 (20 Nov 2026)
1-year return
132.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: LAURUSLABS

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.